Follow CVS Health to never miss an important update.
CVS shared details for its 2027 Medicare plans, focusing on affordability to stay competitive. The plans include no-cost physicals and vaccines, alongside zero-dollar copays for common drugs at its pharmacies. These benefits are designed to keep members within the CVS ecosystem, using its own clinics and drugstores to provide care.
This matters because the health insurance business has struggled recently with rising medical costs. By offering these specific benefits, CVS aims to attract more members while steering them toward its own lower-cost care settings, like Oak Street Health clinics. If this strategy works, it helps stabilize the insurance segment's profit margins, which is a key part of our view on the stock.
Source: PRNewsWire
The company announced that the newest version of the COVID-19 vaccine is now available for both scheduled appointments and walk-ins. Most insurance plans cover these shots at no cost to the patient. While vaccine rollouts are now a routine part of the pharmacy business, they remain a steady driver of foot traffic to CVS stores. This helps the retail side of the business, which relies on pharmacy visits to pull customers into the aisles for other higher-margin purchases.
Source: PRNewsWire
UBS adjusted its target price while maintaining a positive outlook on the company. This move brings their target closer to the average across all analysts, which currently sits at $111. A target trim without a rating change is usually a routine adjustment to reflect recent market prices rather than a shift in how the firm views the business. With the stock currently trading near $95, UBS still sees room for the price to rise.
Source: UBS
Recent results from across the health insurance industry suggest that the high medical costs that have squeezed profits lately may be starting to level off. For a company like CVS, which owns the insurer Aetna, keeping these costs under control is essential for its insurance business to be profitable.
When medical spending is predictable, the company can price its plans more accurately and keep more of the premiums it collects. This industry-wide trend is a helpful sign that the most difficult period of rising healthcare utilization might be passing.
Source: Forbes
Argus Research raised its price target for the company from $104 to $114 while keeping its buy rating. This move suggests more confidence in the company's ability to grow, even as the stock currently trades around $93. Across all the firms that follow the company, the average target price now sits at $110. While one firm's target change is a routine update, the collective view from analysts remains higher than where the stock is priced today.
Source: Argus Research
Management has a long record of beating their own targets, though a recent miss shows they are still wrestling with the high costs of their insurance business.
| Expectation | |
|---|---|
| EPS | $1.64 |
| Revenue | $104.76B |